| Literature DB >> 25998063 |
Renaid B Kim1, Cameron W Irvin1, Keval R Tilva1, Cassie S Mitchell1.
Abstract
Numerous sub-cellular through system-level disturbances have been identified in over 1300 articles examining the superoxide dismutase-1 guanine 93 to alanine (SOD1-G93A) transgenic mouse amyotrophic lateral sclerosis (ALS) pathophysiology. Manual assessment of such a broad literature base is daunting. We performed a comprehensive informatics-based systematic review or 'field analysis' to agnostically compute and map the current state of the field. Text mining of recaptured articles was used to quantify published data topic breadth and frequency. We constructed a nine-category pathophysiological function-based ontology to systematically organize and quantify the field's primary data. Results demonstrated that the distribution of primary research belonging to each category is: systemic measures an motor function, 59%; inflammation, 46%; cellular energetics, 37%; proteomics, 31%; neural excitability, 22%; apoptosis, 20%; oxidative stress, 18%; aberrant cellular chemistry, 14%; axonal transport, 10%. We constructed a SOD1-G93A field map that visually illustrates and categorizes the 85% most frequently assessed sub-topics. Finally, we present the literature-cited significance of frequently published terms and uncover thinly investigated areas. In conclusion, most articles individually examine at least two categories, which is indicative of the numerous underlying pathophysiological interrelationships. An essential future path is examination of cross-category pathophysiological interrelationships and their co-correspondence to homeostatic regulation and disease progression.Entities:
Keywords: Mitochondria; calcium; excitotoxicity; gliosis; neuropathology; protein aggregation; reactive oxygen species; rotarod
Mesh:
Substances:
Year: 2015 PMID: 25998063 PMCID: PMC4724331 DOI: 10.3109/21678421.2015.1047455
Source DB: PubMed Journal: Amyotroph Lateral Scler Frontotemporal Degener ISSN: 2167-8421 Impact factor: 4.092
Figure 1. SOD1-G93A transgenic mouse model research categorized by article topic frequency based on a nine-category pathophysiological function ontology. For each category, the graph illustrates the absolute article count and percentage of the total SOD1-G93A articles with primary data based on word frequency searches of the title, figure captions, and within figure text. Articles are typically classified under two or three categories due to the many inherent biological and pathological inter-category relationships.
Figure 2. Field map of the most prevalent SOD1-G93A transgenic mouse research topics. The sizes of the boxes represent the relative term frequency. The map illustrates categorical terms required to encompass at least 85% of the articles classified to each of the nine categories: Apoptosis, Axonal transport, Chemistry, Energetics, Excitability, Inflammation, Oxidative stress, Proteomics, and Systemic.
The 12 most common terms or phrases per category are presented with a description and the resultant number of articles (A) and figures (F). Note that the 12 terms provided more than 85% coverage in each category (see Test sets).
| Axonal Transport | A | F | Description/Significance |
| retrograde, retrogradely | 44 | 96 | The movement of dynein cargoes towards the cell body |
| neurite, neurites | 38 | 53 | A projection from the cell body, so an axon or dendrite. |
| dynein | 20 | 84 | The motor protein that is responsible for carrying cargoes retrogradely |
| microtubule, microtubules | 17 | 38 | Neural structure or “tracks” on which dynein and kinesin travel. |
| vesicle | 17 | 38 | Transport unit often carried by dynein and kinesin. |
| anterograde, anterogradely | 16 | 40 | The movement of kinesin cargoes from soma towards neuromuscular junction |
| Synaptosome(s) | 11 | 52 | A type of vesicle transported in the axon |
| axon terminal, projection | 10 | 13 | Catch-all terms for detecting axonal transport papers. |
| kinesin | 7 | 15 | The motor protein that is responsible for carrying cargoes anterogradely |
| loa | 7 | 28 | “Legs at Odd Angles” - mutation that affects dynein “legs” ( |
| neurofilament* transport | 5 | 16 | Neural structure element carried via “slow” axonal transport. |
| wallerian | 4 | 9 | Wallerian Degeneration is the degeneration of an axon. |
| Chemistry | A | F | Description/Significance |
| copper, Cu2+ | 58 | 236 | Used by SOD1 |
| zinc, Zn2+ | 53 | 216 | Used by SOD1 |
| metal, metals | 35 | 92 | Catch-all terms for detecting data discussing metals |
| luciferase | 31 | 41 | An oxidative enzyme used in assays |
| iron, Fe, Fe2+ | 17 | 44 | Involved in Fenton reaction, which produces hydroxyl radical |
| HO-1, Heme oxygenase | 17 | 40 | Enzyme that catalyzes the degradation of heme, producing iron |
| vitamin, B12 | 16 | 48 | Tried as a treatment ( |
| lithium | 8 | 46 | Tried as a treatment ( |
| ferritin | 8 | 14 | Controls iron in a cell |
| NaHCO3 | 5 | 10 | Used as a buffer in various experiments, particularly those assessing metalation |
| Salubrinal | 4 | 11 | Used to suppress SOD1 activity ( |
| VPA | 4 | 9 | Valproic acid. Tried as a treatment ( |
| Energetics | A | F | Description/Significance |
| mitochondrial, mitochondria, mito, mitochondrion, | 194 | 773 | Produce ATP, involved in cellular respiration & calcium homeostasis. |
| calcium, Ca2, Ca2+, ca | 100 | 238 | Required for respiration, excitability, and muscle contraction. |
| Cox, complex IV | 80 | 135 | Last enzyme in the respiratory electron transport chain |
| ATP, ADP, ATPase | 74 | 129 | Energy units made or used in cellular respiration |
| cytochrome, cytochrome c | 69 | 141 | Transfers electrons from complex III – IV |
| phosphorylation | 47 | 89 | Process of adding a phosphate group to a protein, turning it “on” or “off” |
| metabolism, metabolic | 43 | 80 | General term encompassing energy harvesting |
| complex I | 28 | 51 | Element of the electron transport chain of mitochondrial respiration |
| glucose | 25 | 45 | Main “fuel” for cellular respiration |
| creatine | 23 | 75 | Increases the formation of ATP |
| succinate | 23 | 35 | Encompasses Succinate Dehydrogenase, aka complex II, role in respiration |
| depolarization | 19 | 37 | Measure of mitochondrial respiration |
| Excitability | A | F | Description/Significance |
| Glutamate | 108 | 401 | Excess extracellular glutamate causes neuronal degeneration |
| GLT1, GLT-1, EAAT2, EAAT | 56 | 188 | Glutamate transporters; decreases observed in ALS patients and G93A mice |
| Na, Na+ | 52 | 112 | Required for action potential; ions enter cell upon activation of glutamate receptors |
| Excitotoxicity, excitatory, | 48 | 137 | Terms describing toxic over-excitation |
| AMPA | 35 | 107 | α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid- glutamate receptor mediating fast excitatory transmission |
| cmap, cmaps | 35 | 53 | Compound muscle action potential-summation of several action potentials over several muscle fibers in one area |
| riluzole | 33 | 85 | Sodium channel blocker; the only FDA-approved drug for ALS. |
| NMDA | 27 | 43 | N-methyl-D-aspartate- glutamate receptor mediating slow excitatory transmission |
| GABA | 22 | 50 | ϒ-Aminobutyric acid- chief inhibitory neurotransmitter in mammals |
| GluR*, GluR1, GluR2, GluR | 20 | 60 | Glutamate receptors: Down-regulation of GluR2 leads to excess Ca2 + influx |
| glutamine | 16 | 34 | Neurologically inactive form - precursor - of glutamate |
| aspartate | 16 | 32 | Stimulates NMDA receptors, but not as strongly as glutamate does |
| Oxidative stress | A | F | Description/Significance |
| H2O2, Hydrogen peroxide | 69 | 129 | Free radical. Relatively weak but can produce stronger oxidants. |
| oxide | 47 | 154 | Catch-all term for elements causing oxidation |
| ROS, reactive oxygen species | 47 | 90 | Reactive molecules containing oxygen. Source of free radicals. |
| GSH, glutathione | 45 | 101 | Antioxidant that prevents damage from free radicals. |
| nitric, nitric oxide | 43 | 145 | Also known as NO. Common type of free radical. |
| Peroxidase, Peroxidation | 36 | 84 | Assist in oxidative degradation; activity is enhanced in ALS mice |
| nNOS, NOS | 34 | 68 | Produces NO upon stimulation by inflammatory cytokines |
| Peroxide, peroxides | 26 | 44 | Catch-all term for any peroxide. See hydrogen peroxide. |
| MDA | 15 | 20 | Marker for oxidative stress |
| Nrf2 | 15 | 73 | Involved in antioxidant and anti-inflammatory defense ( |
| GSSG | 14 | 19 | Oxidized form of glutathione |
| DMPO | 11 | 27 | Used in spin trapping to measure the levels of free radicals. |
| Inflammation | A | F | Description/Significance |
| GFAP | 245 | 399 | Glial fibrillary acidic protein-an indicator of the progression of gliosis |
| astrocyte | 233 | 579 | Astroglia that support neural function; assist in scarring following neural damage |
| T-cells, T-cell, CD11b, CD4 | 181 | 331 | Provides neuroprotection |
| microglia, microglial | 172 | 406 | Excess activation leads to neurodegeneration |
| glial cell, glia | 106 | 247 | Catch-all terms for various glial cells. |
| inflam*, neuroinflamm*, immune | 79 | 285 | Catch-all terms for neuroinflammatory processes. |
| TNF, TNF alpha, TNFalpha, TNFa, TNF a, tumor necrosis factor | 66 | 129 | Tumor necrosis factor α. Stimulates immune activation, leading to gliosis |
| IL, IL 6, IL 4, interleukin | 56 | 78 | Interleukins stimulate immune cell activation, leading to gliosis |
| macrophage, M2, M1 | 53 | 88 | Regulate immune activity via production of cytokines |
| VEGF | 44 | 124 | Vascular endothelial growth factor. Tried as a treatment ( |
| cytokine, cytokines | 38 | 82 | Catch-all terms microglial priming and immune cell activation elements |
| LPS | 33 | 56 | Lipopolysaccharide- activates glial cells, inducing gliosis |
| Apoptosis | A | F | Description/Significance |
| caspase | 122 | 225 | Key apoptotic signal |
| apoptosis, apoptotic | 114 | 294 | Programmed cell death |
| akt | 43 | 81 | When activated by VGEF possibly acts as an anti-apoptotic factor |
| Bcl 2 | 31 | 85 | A protein involved in both pro and anti-apoptotic mechanisms |
| bax | 25 | 43 | A pro-apoptotic protein |
| fmk | 19 | 27 | Anti-apoptotic signaling pathway |
| p75NTR | 17 | 44 | p75 neurotrophin receptor promotes caspase-dependent axon degeneration |
| p53 | 17 | 38 | Tumor-suppressing protein in apoptosis. |
| L-NAME | 15 | 28 | Reduces NO and reverts the pro-apoptotic factors of it |
| FASL | 11 | 26 | Fas ligand; induces apoptosis when bound to its receptor |
| MPTP | 10 | 27 | Neurotoxin that induces apoptosis |
| XIAP | 9 | 15 | X-linked inhibitor of apoptosis protein |
| Proteomics | A | F | Description/Significance |
| Aggregate(s), aggregation, | 168 | 575 | Aggregates of mutant, misfolded proteins are a hallmark of ALS |
| ubiquitin | 89 | 165 | Affects protein degradation, trans-location, and interaction |
| Kinase(s) | 65 | 193 | Affects protein activity, signaling; implicated in protein aggregation in ALS |
| protein binding | 58 | 109 | Catch-all term for binding processes of mutant SOD1 leading to aggregation. |
| proteasome, proteasomal | 54 | 143 | Involved in protein degradation. |
| disulfide | 35 | 131 | Disulfide bonds mediate the aggregation process in SOD1 |
| oligomer* | 30 | 40 | Catch-all term for proteins |
| heat shock protein, hsp | 30 | 74 | Response to proteomic stress. Up-regulation extends survival. |
| ER Stress | 27 | 75 | Endoplasmic reticulum stress from unfolded proteins |
| misfolded protein, protein fold change | 27 | 43 | The fold change (misfolded proteins) leads to protein aggregates. |
| protein degradation | 24 | 36 | Dysfunctional degradation of misfolded proteins causes aggregates |
| TDP-43, TDP 43 | 23 | 59 | TAR-DNA binding protein 43. Inclusions commonly found in ALS patients. |
| Systemic | A | F | Description/Significance |
| Density, count or activity of motor neurons (all spellings) | 323 | 483 | Includes functional measures of locomotor activity and assessment of motor neuron degeneration |
| rotarod, rotorod, rot*rod | 217 | 267 | Experimental device and test used to assess mouse motor function |
| disease progression | 205 | 553 | Catch-all term for in vivo observation of disease progression. |
| hindlimb, forelimb, limb, | 173 | 318 | Hindlimb tremors are commonly used as a marker of disease onset |
| body weight | 171 | 233 | Indicator of disease progression; decreases in later stages of the disease. |
| lifespan, life span | 121 | 240 | The total time spent alive for the subject. |
| cumulative survival | 103 | 119 | The endpoint of the disease. Total lifespan of subject. |
| probability of onset | 102 | 109 | The time when symptoms of ALS typically begin to appear. |
| grip, grip strength | 94 | 134 | Test assessing mouse's ability to grip; indicator of motor function/progression |
| in vivo, invivo | 88 | 209 | “Within the living” - encompasses all experiments performed on live test subjects. |
| gastrocnemius | 75 | 151 | Large muscle found in the hindlimb, easy to access and evaluate. |
| fall | 59 | 73 | The action of falling down, usually due to inability to stand. |
Figure 3. Field map of the inflammation categories based on their pathophysiological properties and significance to demonstrate the variety of terms that were searched. The frequency search reveals that a few measures are used for specific cell types, e.g. GFAP expression was much more heavily used (by 259 articles) compared to ApoE (six articles).